Cellectis gets access to a Japanese firm's iPS cell patents

10/18/2010 | Google

France's Cellectis has secured iPS Academia Japan's patents for induced pluripotent stem cells, according to a report by Kyodo News. The agreement allows Cellectis to use the cells to create treatments and to test the efficacy of drug candidates.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC